BenzingaSeptember 30, 2026 at 10:00 AM NY27 Days Ago
JP Morgan Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $369
JP Morgan analyst Jessica Fye maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Overweight and lowers the price target from $375 to $369.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
